Insights

Innovative Biotechnology Focus Sylentis specializes in gene silencing and RNA interference technologies, positioning itself as a leader in innovative ophthalmologic therapies, creating opportunities to offer advanced biotech solutions and research tools.

Strategic Industry Position As a subsidiary of PharmaMar with recent leadership appointments, Sylentis is expanding its developmental pipeline, making it a promising partner for collaborations in cutting-edge gene therapy and drug development projects.

Growth and Funding Potential With revenues ranging from 1 to 10 million dollars and ongoing industry momentum, Sylentis presents a growing market opportunity for suppliers of biotech research infrastructure, laboratory services, and specialized therapeutic delivery technologies.

Technology Stack Compatibility Using popular platforms like WordPress, Google Analytics, and Bootstrap indicates a modern digital presence, enabling targeted outreach through digital marketing, analytics solutions, and web development partnerships.

Market Expansion Opportunities Focusing on ophthalmologic conditions such as glaucoma and dry eye syndrome, Sylentis offers potential for sales of medical devices, diagnostics, and patient management solutions tailored to ophthalmology specialists and clinics.

Similar companies to SYLENTIS

SYLENTIS Tech Stack

SYLENTIS uses 8 technology products and services including WordPress, Microsoft 365, Google Fonts API, and more. Explore SYLENTIS's tech stack below.

WordPress
Content Management System
Microsoft 365
Email
Google Fonts API
Font Scripts
spin.js
Javascript Frameworks
Isotope
Javascript Libraries
DPD
Logistics
Bootstrap
UI Frameworks
Google Analytics
Web Analytics

Media & News

Sylentis hires Andreas Segerros as Chief Executive Officer.
Sylentis, a PharmaMar group company, appoints Andreas Segerros as Chief Executive Officer.
May 28, 2024 | pharmamar.com

SYLENTIS's Email Address Formats

SYLENTIS uses at least 1 format(s):

SYLENTIS Email Formats	Example	Percentage
FLast@sylentis.com	JDoe@sylentis.com	50%
FLast@sylentis.com	JDoe@sylentis.com	50%

Frequently Asked Questions

Where is SYLENTIS's headquarters located?

SYLENTIS's main headquarters is located at Parque Científico de Madrid, c/ Santiago Grisolía, 2 Tres Cantos, Madrid 28760, ES. The company has employees across 1 continents, including Europe.

What is SYLENTIS's phone number?

You can contact SYLENTIS's main corporate office by phone at

+34-918-04-7****

. For more prospecting data, LeadIQ has access to up-to-date and accurate contact information within our platform. Find, capture, and sync contact data to your CRM and sales tools in one click.

What is SYLENTIS's official website and social media links?

SYLENTIS's official website is sylentis.com and has social profiles on LinkedIn Crunchbase.

What is SYLENTIS's SIC code NAICS code?

SYLENTIS's SIC code is 8733 - Noncommercial Research Organizations NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does SYLENTIS have currently?

As of October 2025, SYLENTIS has approximately 53 employees across 1 continents, including Europe. Key team members include Chief Executive Officer: A. S.Head Of Clinical Operations: A. B.Laboratory Head - Molecular And Cell Biology: F. R. O.. Explore SYLENTIS's employee directory with LeadIQ.

What industry does SYLENTIS belong to?

SYLENTIS operates in the Biotechnology Research industry.

What technology does SYLENTIS use?

SYLENTIS's tech stack includes WordPressMicrosoft 365Google Fonts APIspin.jsIsotopeDPDBootstrapGoogle Analytics.

What is SYLENTIS's email format?

SYLENTIS's email format typically follows the pattern of FLast@sylentis.com. Find more SYLENTIS email formats with LeadIQ.

When was SYLENTIS founded?

SYLENTIS was founded in 2006.

SYLENTIS

Biotechnology ResearchSpain51-200 Employees

Sylentis is an European biotechnological company founded in 2006. Sylentis focuses on researching new therapeutic approaches based on gene silencing. Our company is specialised in developing ophtalmologic   therapies via interference RNA, a powerful tool for rational drug design.

Most advanced product of the company are treatments for glaucoma and dry eye syndrome.

Sylentis is a wholly owned member of PharmaMar (www.pharmamar.com)

Company Overview

Headquarters: Parque Científico de Madrid, c/ Santiago Grisolía, 2 Tres Cantos, Madrid 28760, ES
Phone number: +34-918-04-7****
Website: sylentis.com
SIC Code: 8733 - Noncommercial Research Organizations
NAICS Code: 541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Founded: 2006
Employees: 51-200